Skip to main navigation

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

April 25, 2019

Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting

Additional Formats

PDF Version

March 28, 2019

Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

March 7, 2019

Kodiak Sciences to Present at the Barclays Global Healthcare Conference

Additional Formats

PDF Version

February 8, 2019

Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting

Additional Formats

PDF Version

December 24, 2018

Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes

Additional Formats

PDF Version

December 21, 2018

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate

Additional Formats

PDF Version

November 16, 2018

Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

October 10, 2018

Kodiak Sciences Inc. Announces Closing of Initial Public Offering

Additional Formats

PDF Version

October 3, 2018

Kodiak Sciences Inc. Announces Pricing of Initial Public Offering

Additional Formats

PDF Version

September 17, 2018

Kodiak Sciences Expands Leadership with Industry Veterans Including Appointment of Jason Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Next page
Last page

Displaying 61 - 70 of 77

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2021 Kodiak Sciences Inc.